PumasAI

What PumasAI does

PumasAI (legally Pumas-AI Inc.) is a US-based private healthcare intelligence company headquartered in Dover, Delaware, that builds AI-driven software for clinical pharmacology and pharmacometrics in drug development. The company's core platform, Pumas 2.8, combines DeepPumas—a data analytics engine for pharmacometric modeling and simulation—with PumasAide, an integrated generative AI assistant for workflow guidance. Supporting offerings include a freemium Academic Access program for non-commercial research and education, and Consulting Services that help clients identify the shortest regulatory approval pathway. The platform is positioned to accelerate data-driven decisions in drug development, with the company reporting $1B+ in cumulative time-and-cost savings across 60+ clients and 26+ successful regulatory submissions using its tools.

The company serves three customer segments: pharmaceutical and biotechnology companies (primary), academic and research institutions, and individual healthcare professionals and clinicians. PumasAI monetizes through enterprise subscription licensing with quote-based annual pricing and complementary professional services engagements, supported by an enterprise field sales motion with direct engagement CTAs. A high-performance computing cluster and the newly established Computational Lab for Quantitative Sciences in Coimbatore, India—created in partnership with PSG Institute of Medical Sciences and Research and the Society of Pharmacometrics and Health Analytics Sciences—provide the underlying infrastructure for advanced modeling and AI-driven research.

Strategically, PumasAI is investing in international expansion (India office, July 2026), AI capability deepening (PumasAide, 2026), and ecosystem buildout through academic partnerships and a freemium pipeline. The company has received three consecutive years (2024, 2025, 2026) of the Clinical Pharmacology & Pharmacometrics Innovator of the Year award from Global Health & Pharma News. Notable data gaps include the absence of disclosed funding history, named customer logos, leadership team details, revenue figures, and founding date.

Name

PumasAI

Legal name

Pumas-AI Inc.

Website

https://pumasai.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

PumasAI is a private US healthcare intelligence company that builds AI-driven pharmacometric modeling and simulation software for pharmaceutical and biotechnology drug development, supplemented by consulting services and a freemium academic access program.

Ownership category

akta.pro rank

Headquarters

HQ city

Dover

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Software Products: Data analytics tools including DeepPumas and the Pumas 2.8 platform for pharmaceutical and healthcare organizations to support drug development decision-making.
2. Consulting Services: Strategic consulting engagements to help clients navigate regulatory approval processes and optimize drug development pathways.
3. Academic Access Program: Complimentary access to advanced modeling tools for non-commercial research and education purposes, building market presence and talent pipeline.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

PumasAI develops and sells Pumas 2.8 (with the PumasAide AI assistant) and DeepPumas, an AI-driven data analytics platform for clinical pharmacology, pharmacometrics, and drug development decision-making used by pharmaceutical and biotech companies. The company also provides expert consulting services to help clients navigate regulatory approval and offers complimentary Academic Access to its modeling tools for non-commercial research and education.

Product overview

PumasAI offers a unified software platform focused on drug development and healthcare delivery. The core product is DeepPumas (Pumas), a data analytics platform for pharmacometric modeling and simulation. Pumas 2.8 introduces PumasAide, an AI assistant feature. The portfolio includes Academic Access (complimentary tools for non-commercial research/education) and Consulting Services (regulatory strategy support). Together, these offerings serve pharmaceutical and biotech companies, academic researchers, and healthcare professionals to advance AI-driven drug development.

Differentiator

Problem solved

Functional benefit

Products and services

• DeepPumas (Pumas Platform) Data analytics platform for pharmaceutical and biotech companies that enables data-driven decision-making in drug development through advanced pharmacometric modeling, simulation, and analytics. Targeted at organizations developing drug products that require computational tools for regulatory approval.
• Academic Access Program Complimentary access to PumasAI's advanced pharmacometric modeling and quantitative sciences tools for academic institutions and non-commercial research and education use. Functions as a freemium offering that builds a future talent and customer pipeline.
• Consulting Services Expert consulting engagements to help pharmaceutical and biotech clients find the shortest development path for regulatory approval, leveraging pharmacometric expertise and regulatory strategy alongside the Pumas software platform.

Quantifiable outcome

• $1B+ saved in money and time for 60+ clients
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• PSG Institute of Medical Sciences and ResearchcoreStrategic or Co-development Partner · 22 July 2026PumasAI partnered with PSG Institute of Medical Sciences and Research to establish India's first Computational Lab for Quantitative Sciences in Coimbatore, Tamil Nadu. The facility is powered by a high-performance computing cluster designed to advance AI-driven drug development by providing students, researchers, clinicians, and healthcare professionals with advanced computational resources for research, education, and clinical pharmacology applications. The collaboration aims to bridge academia and industry while preparing a skilled workforce.
• Society of Pharmacometrics and Health Analytics SciencescoreStrategic or Co-development Partner · 22 July 2026Partnered with Society of Pharmacometrics and Health Analytics Sciences to establish India's first Computational Lab for Quantitative Sciences. This collaboration supports the growing demand for expertise in pharmacometrics, quantitative sciences, and AI-enabled healthcare innovation, bridging academia and industry through shared computational resources and research initiatives.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Metrum Research Group: Metrum Research Group provides pharmacometric consulting, modeling, and open-source tooling (e.g., mrgsolve) used by the same clinical pharmacology teams that PumasAI targets. It is a long-standing specialist peer in model-informed drug development.
• Certara: Certara is the dominant vendor in pharmacokinetic/pharmacodynamic modeling, regulatory science software, and biosimulation services for pharma. It directly competes with PumasAI's Pumas platform and consulting offering for the same model-informed drug development buyers.
• Mango Solutions: Mango Solutions delivers R-based data science consulting and validated packages for pharmaceutical modeling, statistics, and reporting. It overlaps with PumasAI in serving quantitative pharmacology and biostatistics groups in pharma.

Others

• MathWorks: MathWorks' MATLAB and Simulink are widely used by clinical pharmacology and pharmacometrics teams for modeling and simulation. It is a complementary/adjacent computational platform rather than a direct competitor to PumasAI.
• SAS Institute: SAS provides analytics and statistical software used extensively in pharma R&D, clinical trial reporting, and regulatory submissions. It is an adjacent analytics platform whose tools PumasAI's customers often also use.

Broad incumbents

• Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software for drug discovery and materials, including pharma-grade platforms like LiveDesign. It is a broader incumbent in computational drug development that competes for similar pharma R&D budget.
• Cytel: Cytel offers clinical development analytics, biostatistics software (East, Solara), and services across the trial lifecycle. It is a broader incumbent adjacent to PumasAI's modeling and regulatory submission support capabilities.

Emerging players

• L7 Informatics: L7 Informatics provides a data and workflow platform for clinical research, genomics, and biopharma R&D. It is an emerging player in clinical research informatics that addresses overlapping buyer personas to PumasAI.
• Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company that combines generative AI, target discovery, and clinical development. It overlaps with PumasAI's AI-for-drug-development thesis but is more upstream in discovery rather than clinical pharmacology.
• Recursion Pharmaceuticals: Recursion applies AI and high-throughput biology to drug discovery and is building a vertically integrated pipeline. It is an emerging AI-for-pharma peer that competes for narrative and capital attention in the same AI-drug-development category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights5 records

Customer concentration

• Xx.com/pumas_ai
• YouTubeyoutube.com/@pumasai

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PumasAI